Success Metrics

Clinical Success Rate
70.4%

Based on 76 completed trials

Completion Rate
70%(76/108)
Active Trials
41(25%)
Results Posted
89%(68 trials)
Terminated
32(20%)

Phase Distribution

Ph not_applicable
13
8%
Ph early_phase_1
4
2%
Ph phase_1
58
36%
Ph phase_4
1
1%
Ph phase_2
72
44%
Ph phase_3
14
9%

Phase Distribution

62

Early Stage

72

Mid Stage

15

Late Stage

Phase Distribution162 total trials
Early Phase 1First-in-human
4(2.5%)
Phase 1Safety & dosage
58(35.8%)
Phase 2Efficacy & side effects
72(44.4%)
Phase 3Large-scale testing
14(8.6%)
Phase 4Post-market surveillance
1(0.6%)
N/ANon-phased studies
13(8.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.1%

76 of 115 finished

Non-Completion Rate

33.9%

39 ended early

Currently Active

41

trials recruiting

Total Trials

163

all time

Status Distribution
Active(41)
Completed(76)
Terminated(39)
Other(7)

Detailed Status

Completed76
Terminated32
Recruiting22
Active, not recruiting19
Withdrawn7
unknown6

Development Timeline

Analytics

Development Status

Total Trials
163
Active
41
Success Rate
70.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (2.5%)
Phase 158 (35.8%)
Phase 272 (44.4%)
Phase 314 (8.6%)
Phase 41 (0.6%)
N/A13 (8.0%)

Trials by Status

active_not_recruiting1912%
unknown64%
terminated3220%
recruiting2213%
suspended11%
withdrawn74%
completed7647%

Recent Activity

Clinical Trials (163)

Showing 20 of 163 trialsScroll for more
NCT05436418Phase 1

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Recruiting
NCT04959175Phase 1

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Recruiting
NCT06078696Phase 1

Siplizumab for Sickle Cell Disease Transplant

Terminated
NCT06942039Early Phase 1

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Recruiting
NCT03849651Phase 2

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Active Not Recruiting
NCT07052370Phase 1

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Recruiting
NCT04881240Phase 1

Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Recruiting
NCT03573700Phase 1

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT04318678Phase 1

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Recruiting
NCT07257419Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Recruiting
NCT07428993Phase 2

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

Recruiting
NCT06777979Phase 1

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

Recruiting
NCT04897321Phase 1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Recruiting
NCT04530565Phase 3

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Active Not Recruiting
NCT03577431Phase 1

Liver Transplantation With Tregs at MGH

Active Not Recruiting
NCT03821610Phase 2

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

Active Not Recruiting
NCT04684368Phase 2

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Recruiting
NCT01096368Phase 3

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Completed
NCT03263559Phase 2

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

Completed
NCT02436707Phase 2

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
163